D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 45.1 CNY -3.34% Market Closed
Market Cap: 18.7B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dizal Jiangsu Pharmaceutical Co Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Other Long-Term Assets
ÂĄ17m
CAGR 3-Years
69%
CAGR 5-Years
179%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Long-Term Assets
ÂĄ304.3m
CAGR 3-Years
-29%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Long-Term Assets
ÂĄ405.6m
CAGR 3-Years
39%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Other Long-Term Assets
ÂĄ132.9m
CAGR 3-Years
-37%
CAGR 5-Years
-12%
CAGR 10-Years
9%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Long-Term Assets
ÂĄ1.2B
CAGR 3-Years
21%
CAGR 5-Years
33%
CAGR 10-Years
46%
Imeik Technology Development Co Ltd
SZSE:300896
Other Long-Term Assets
ÂĄ81.1m
CAGR 3-Years
29%
CAGR 5-Years
53%
CAGR 10-Years
N/A
No Stocks Found

Dizal Jiangsu Pharmaceutical Co Ltd
Glance View

Market Cap
18.4B CNY
Industry
Biotechnology

Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.

Intrinsic Value
30.31 CNY
Overvaluation 33%
Intrinsic Value
Price
D

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Other Long-Term Assets?
Other Long-Term Assets
17m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Other Long-Term Assets amounts to 17m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
179%

Over the last year, the Other Long-Term Assets growth was 113%. The average annual Other Long-Term Assets growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 69% over the past three years , 179% over the past five years .

Back to Top